contact@eolo-pharma.com
EOLO PHARMA announced that it has received approval to initiate a Phase 1 clinical trial for MVD1, the company’s investigational small molecule designed to reduce
Our NCE library is composed of 60 novel molecules. Within our pipeline we highlight MVD1, our lead compound for Obesity and its comorbidities.
Eolo Pharma is the result of the passion and dedication of an interdisciplinary team of scientists and entrepreneurs: Carlos Batthyany, Virginia Lopez, Carlos Escande, and María Pía Garat. Founded as a spin-off from the Institut Pasteur de Montevideo and the UDELAR (Universidad de la República Uruguay), we are a leading drug development and discovery platform company with a robust and versatile approach.
Our focus lies in developing novel molecules to address non-communicable disorders such as cardiometabolic, neurodegenerative, and autoimmune disorders. Leveraging a decade of experience working with small molecules, we have built a unique portfolio based on patented technologies and extensive fundamental intellectual property licenses.
Our NCE library is composed of 60 novel molecules. Within our pipeline we highlight MVD1, our lead compound for Obesity and its comorbidities.
Obesity and its comorbidities are becoming pandemic and a prime driver of healthcare burden worldwide. While obesity can be considered an independent disease, it is the primary mediator of metabolic syndrome, the principal risk factor for Type II diabetes and cardiovascular diseases. Whereas obesity is preventable via promotion of healthier nutrition and lifestyle, according to the World Health Organization, in 2016 more than 1.9 billion adults were overweight or obese . Even more, recent reports demonstrate that once the obese phenotype has been established it is extremely difficult to reverse by altering lifestyle. Indeed recent evidence shows that only 5-10% of obese individuals that engage in weight-loss programmes are able to show success after one year.
This failure not only has adverse effect on metabolic syndrome but also affects self-esteem, making even more difficult for patients to engage in future weight-loos attempts. When taken together, these issues affirm the critical need for developing novel pharmacologic strategies for prevention and treatment of obesity and its associated comorbidities.
Eolo Pharma has developed a compound, which we called MVD1, that has anti-obesity properties when tested in preclinical models. By preventing and treating obesity, MVD1 also improves glucose metabolism, making it attractive for the treatment of type II diabetes also. Furthermore, MVD1 shows better results than Metformin, the first line drug for the treatments of type II diabetes in patients. MVD1 works through a completely novel pharmacological action, stimulating resting energy expenditure and fat burning without the need of extra exercise. Together, these data demonstrate MVD1 as a candidate for the treatment of obesity, type II diabetes. Based on that, we aimed to follow the pre-clinical development necessary to perform a Phase IB clinical trial in patients. MVD1 complied with all the required safety requirements by regulatory agencies, strongly suggesting that it may be suitable for further clinical development.